Zai Lab (Zai Lab) Cash per Share : $6.69 (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Zai Lab Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Zai Lab's Cash per Share for the quarter that ended in Mar. 2024 was $6.69.

Zai Lab Cash per Share Historical Data

The historical data trend for Zai Lab's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab Cash per Share Chart

Zai Lab Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash per Share

Get a 7-Day Free Trial

40.36

13.52

14.76

10.50

8.30

Zai Lab Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash per Share	Get a 7-Day Free Trial															9.66	9.03	8.47	8.30	6.69

Zai Lab Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Zai Lab's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	806.451	/	97.2
	=	8.29

Zai Lab's Cash per Share for the quarter that ended in Mar. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	650.78	/	97.3
	=	6.69

Zai Lab (NAS:ZLAB) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Zai Lab Cash per Share Related Terms

Thank you for viewing the detailed overview of Zai Lab's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Zai Lab (Zai Lab) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (NAS:ZLAB) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

ZLAB:Mexico 09688:Hong Kong 1ZLB:Germany 1ZLB:Germany 1ZL:Germany 1ZL:Germany

Address

4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210

Website

https://www.zailaboratory.com

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatment across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

Executives

Harald Reinhart	officer: Chief Medical Officer	4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210
Edmondson Frazor Titus Iii	officer: Chief Legal Officer	4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210
Ying Du	director, officer: Chairwoman & CEO	C/O ZAID LAB LIMITED, 4560 JINKE ROAD, BLDG. 1, 4F, PUDONG, SHANGHAI F4 201210
Rafael Amado	officer: See Remarks	210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Joshua L Smiley	officer: Chief Operating Officer	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Yajing Chen	officer: Chief Financial Officer	314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE MA 02142
Michel Vounatsos	director	BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Peter Wirth	director	37 HANCOCK STREET, BOSTON MA 02114
John D Diekman	director	C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
William Lis	director	PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Richard Gaynor	director	C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Tao Fu	director, officer: President & COO	3175 HANOVER STREET, PALO ALTO CA 94304
Scott W Morrison	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Cho William Ki Chul	officer: Chief Financial Officer	4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210
Kai-xian Chen	director	4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210